A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors

NCT03518554 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer
Head and Neck Cancer
Esophageal Cancer
Other Metastatic Solid Tumors

Interventions

DRUG: JAB-3068

Sponsor

Jacobio Pharmaceuticals Co., Ltd.